US FDA asks firms to check quality of glass drug vials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has expressed concern over several recent incidents of injectable drugs, filled in small-volume glass vials, being recalled due to the formation of glass lamellae (ie glass fragments). The agency is asking manufacturers of these products to re-examine their supplier quality management programme with glass vial manufacturers to prevent such incidents1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.